Symbol not found

:NSTM  
0.00
0.00 (0.00%)
Products

NovelStem Increases NewStem Ownership To 33%, Prepares For FDA Filing For Approval Of Its Stem-Cell Based Anti-Cancer Drug Resistance Diagnostic

Published: 12/01/2020 13:45 GMT
(NSTM) - Novelstem Increases Newstem Ownership to 33% As Newstem Prepares for First-half 2021 FDA Filing for Approval of Its Stem-cell Based Anti-cancer Drug Resistance Diagnostic; Novelstem Initiates Process to Become Publicly-reporting With Sec.
and to Up-lis.